Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00002001
Other study ID # 052B
Secondary ID 02
Status Completed
Phase N/A
First received November 2, 1999
Last updated June 23, 2005

Study information

Verified date September 1991
Source NIH AIDS Clinical Trials Information Service
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To evaluate the immunologic effects of zidovudine and ddI or ddC. To evaluate combined administration of zidovudine and ddI or ddC for clinical efficacy. To evaluate the safety and the tolerance of the coadministration of zidovudine and ddI or ddC.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 13 Years and older
Eligibility Inclusion Criteria

Concurrent Medication:

Allowed:

- Patients with PCP may be randomized to study medication after contacting the sponsor and following a minimum 7-day course of therapy resulting in stabilization of their disease. Patients with stabilized disease must have fever < 39 C for at least 48 hours, p02 (on room air) > or = 60 mm and an A/A gradient < or = 30 mm.

- Prophylaxis for PCP.

Patients must have the following:

- HIV-1 seropositive by any federally licensed ELISA.

- Willingness to give informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- Any immediately life-threatening infection or medical condition present at time of study entry.

- Any active opportunistic infection requiring chronic therapy with any of the agents listed in the exclusion concurrent medication section.

- Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.

- Kaposi's sarcoma with visceral involvement or requiring systemic cytotoxic chemotherapy.

- AIDS dementia complex, > or = Stage 2.

- History of zidovudine induced toxicity.

- Prior history of acute pancreatitis during the past two years or chronic pancreatitis.

- Grade 2 neuropathy.

- Intractable diarrhea.

- History of seizures within the past six months or current requirement of anticonvulsants.

- Past or current heart disease.

- Fever > 39 C at entry.

Concurrent Medication:

Current requirement of anticonvulsants.

- Excluded:

- It is intended that patients developing new opportunistic infections during the course of the study will continue study participation, unless required therapy is associated with significant neurologic or hematologic toxicities, in which case the study medication may be temporarily discontinued.

- Ganciclovir.

- Chloramphenicol.

- Cisplatinum.

- Iodoquinol.

- Systemic Pentamidine.

- Disulfiram.

- Ethionamide.

- Glutethimide.

- Gold.

- Hydralazine.

- Metronidazole.

- Sodium Cyanate.

- Thalidomide.

- Vincristine.

- Allopurinol.

- Probenecid.

Concurrent Treatment:

Excluded:

- Radiation therapy. (with the exception of electron beam therapy to an area of < 100cm/m2.)

Patients with the following are excluded:

- Any immediately life-threatening infection or medical condition present at time of study entry.

- Any active opportunistic infection requiring chronic therapy with any of the agents listed in the exclusion concurrent medication section.

- Active alcohol or drug abuse, sufficient in the investigator's opinion to prevent compliance with study therapy.

- Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.

- Kaposi's syndrome with visceral involvement or requiring systemic cytotoxic chemotherapy.

- AIDS dementia complex, > or = Stage 2.

- History of zidovudine induced toxicity.

- Any experimental therapy within 30 days.

- Prior history of acute pancreatitis during the past two years or chronic pancreatitis.

- Grade 2 neuropathy.

- Intractable diarrhea.

- History of seizures within the past six months or current requirement of anticonvulsants.

- History of past or current heart disease.

- Fever > 39 C at entry.

Prior Medication:

Excluded:

- Any anti-HIV therapy (other than zidovudine), biologic response modifiers, or pharmacologic doses of corticosteroids within eight weeks of entry (except for the management of severe PCP, in which case duration is not to exceed 21 days).

- Zidovudine therapy for greater than four weeks or prior discontinuation due to drug toxicity.

- Prior therapy with ddI, ddC, D4T, or interferon.

- Any experimental therapy within 30 days.

- Therapy within 30 days with neurotoxic drugs.

Prior Treatment:

Excluded:

- Radiation therapy within two weeks of entry or likely to require radiation therapy (with the exception of electron beam therapy to an area of < 100cm/m2).

Active alcohol or drug abuse, sufficient in the investigator's opinion, to prevent compliance with study therapy.

Study Design

Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Zidovudine

Zalcitabine

Didanosine


Locations

Country Name City State
Australia Saint Vincent's Hosp Med Centre Darlinghurst
Puerto Rico San Juan Veterans Administration Med Ctr San Juan
United States Univ of Colorado Health Sciences Ctr Denver Colorado
United States Vanderbilt School of Medicine Nashville Tennessee
United States Georgetown Univ Med Ctr / Main Hosp 4 Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Glaxo Wellcome

Countries where clinical trial is conducted

United States,  Australia,  Puerto Rico, 

References & Publications (1)

Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 1996 Sep;70(9):5922-9. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2